SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) October 8, 2003 (October 7, 2003)
REGENERON PHARMACEUTICALS, INC.
| NEW YORK (State or other jurisdiction of incorporation) |
0-19034 (Commission File Number) |
No. 13-3444607 (IRS Employer Identification No.) |
| 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY (Address of principal executive offices) |
10591-6707 (Zip Code) |
| Registrant’s telephone number, including area code | (914) 347-7000 |
NOT APPLICABLE
(Former name or former address, if changed since last report)
Page 1 of 7
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURE | ||||||||
| PRESS RELEASE | ||||||||
INFORMATION TO BE INCLUDED IN REPORT
Item 5. Other Events.
On October 7, 2003, the Company issued a press release, a copy of which is included as an exhibit to this filing.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99(a) Press Release dated October 7, 2003.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Regeneron Pharmaceuticals, Inc. | ||
| By: /s/ Stuart Kolinski | ||
|
Stuart Kolinski Vice President & General Counsel |
||
| Date: October 8, 2003 |
-3-